| GTO ID | GTC2360 |
| Trial ID | NCT04406272 |
| Disease | Glioblastoma |
| Altered gene | TNFR1::Fas |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | VB111|ofranergene obadenovec |
| Co-treatment | Surgery|Bevacizumab |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | Dana-Farber Cancer Institute |
| Other ID(s) | 19-792 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort 1 | |||||||||
|
|||||||||